PRAX Stock Analysis: Praxis Precision Medicines | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 10.270m USD | 12M Return: 649.6% | US74006W2070 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 139M
Warnings
Tailwinds
Seasonality 5.8 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Praxis Precision Medicines, Inc. (PRAX) is a U.S.-based, clinical-stage biopharmaceutical company developing therapies for central nervous system (CNS) disorders linked to neuronal excitation-inhibition imbalance. Headquartered in Boston, Massachusetts and incorporated in 2015, the company operates two discovery platforms: Cerebrum for small molecule therapies and Solidus for antisense oligonucleotide (ASO) drug development.
The companys lead clinical assets include ulixacaltamide, which has reached the NDA stage for essential tremor, and relutrigine, an NDA-stage small molecule for SCN2A- and SCN8A-related developmental and epileptic encephalopathies (DEE) that is also in Phase 3 trials for broader DEE indications. Additional late-stage candidates include vormatrigine (Phase 3 for adjunctive focal epilepsy, Phase 2 for monotherapy) and Elsunersen, an ASO in Phase 3 for SCN2A-DEE. A pre-clinical pipeline (PRAX-020, PRAX-080, PRAX-090, PRAX-100) targets additional genetic epilepsies including KCNT1, PCDH19, SYNGAP1, and SCN2A loss-of-function disorders.
As a clinical-stage biotechnology company, Praxis has not yet generated commercial product revenue and typically depends on capital markets and collaboration agreements to fund development. The company holds a cooperation and license agreement with RogCon Inc. and a research collaboration with Ionis Pharmaceuticals, Inc., a recognized leader in antisense oligonucleotide technology, which supports its Solidus platform.
- Ulixacaltamide FDA approval decision for essential tremor
- Relutrigine and vormatrigine Phase 3 readouts in epilepsies
- Cash burn and dilution risk as clinical-stage biotech
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.22 > 0.02 and ΔFCF/TA 20.19 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.22 > 3% & CFO -305.7m > Net Income -339.1m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 15.73 > 1.5 & < 3 |
| Outstanding Shares: last quarter (29.1m) vs 12m ago 35.65% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 1.71%; Δ -1.71% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.52 (Total Current Assets 771.9m - Total Current Liabilities 49.1m) / Total Assets 1.39b |
| B: -0.95 (Retained Earnings -1.32b / Total Assets 1.39b) |
| C: -0.37 (EBIT TTM -339.1m / Avg Total Assets 921.5m) |
| D: 27.34 (Book Value of Equity 1.34b / Total Liabilities 49.1m) |
| Altman-Z'' = 26.55 = AAA |
As of August 29, 2026, the stock is trading at USD 344.75 with a total of 282,849 shares traded. Over the past week, the price has changed by -8.30%, over one month by +16.54%, over three months by -2.23% and over the past year by +649.62%.
Current recommended Stop Loss: 320.60 (which is 7% or 1.2 ATR below the current price).
Praxis Precision Medicines has received a consensus analysts rating of 4.42. Therefore, it is recommended to buy PRAX.
- StrongBuy: 8
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 1
| Analysts Target Price | 638.7 | 85.3% |
P/S = 144.694
P/B = 7.8567
Revenue TTM = 0.0 USD
EBIT TTM = -339.1m USD
EBITDA TTM = -339.0m USD
Long Term Debt = unknown (0.0)
Short Term Debt = 1.09m USD (from shortTermDebt, last quarter)
Debt = 2.52m USD (from shortLongTermDebtTotal, last quarter) + Leases 1.44m
Net Debt = -756.0m USD (calculated: Debt 2.52m - CCE 758.6m)
Enterprise Value = 9.51b USD (10.3b + Debt 2.52m - CCE 758.6m)
Interest Coverage Ratio = unknown (Ebit TTM -339.1m / Interest Expense TTM 0.0)
EV/FCF = -31.09x (Enterprise Value 9.51b / FCF TTM -306.0m)
FCF Yield = -3.22% (FCF TTM -306.0m / Enterprise Value 9.51b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 140k) / Revenue TTM)
Tobins Q-Ratio = 6.84 (Enterprise Value 9.51b / Total Assets 1.39b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 2.52m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -267.9m (EBIT -339.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 15.73 (Total Current Assets 771.9m / Total Current Liabilities 49.1m)
Debt / Equity = 0.00 (Debt 2.52m / totalStockholderEquity, last quarter 1.34b)
Debt / EBITDA = 2.23 (negative EBITDA) (Net Debt -756.0m / EBITDA -339.0m)
Debt / FCF = 2.47 (negative FCF - burning cash) (Net Debt -756.0m / FCF TTM -306.0m)
Total Stockholder Equity = 993.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -36.80% (Net Income -339.1m / Total Assets 1.39b)
RoE = -34.15% (Net Income TTM -339.1m / Total Stockholder Equity 993.2m)
RoCE = -34.15% (EBIT -339.1m / Capital Employed (Equity 993.2m + L.T.Debt 0.0))
RoIC = -19.96% (negative operating profit) (NOPAT -267.9m / Invested Capital 1.34b)
WACC = 13.17% (E(10.3b)/V(10.3b) * Re(13.17%) + D(2.52m)/V(10.3b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 13.17% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 93.15 | Cagr: 38.92%
[DCF] Fair Price = unknown (Cash Flow -306.0m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.65 | # QB: 2
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: N/A | # QB: 0
EPS current Quarter (2026-09-30): EPS=-3.63 | Chg30d=+9.80% | Revisions=+0% | Analysts=17
EPS current Year (2026-12-31): EPS=-13.94 | Chg30d=+9.05% | Revisions=+17% | GrowthEPS=-3.4% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-9.29 | Chg30d=+3.75% | Revisions=-40% | GrowthEPS=+33.3% | GrowthRev=+39590.5%
[Analyst] Revisions Ratio: -10% (up=3, down=4)